ArticleJournal of clinical medicine2026
Regression of Anabolic-Androgenic Steroid-Associated Cardiomyopathy Eight Years After Cessation of Anabolic-Androgenic Steroid Abuse: A Case Report and Literature Review.
Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The non-medical use of anabolic-androgenic steroids (AAS) is widespread among strength-training athletes and, increasingly, among men who have no medical indication for testosterone therapy. The cardiotoxic profile of these drugs includes concentric myocardial hypertrophy, systolic and diastolic dysfunction, myocardial fibrosis and an elevated risk of sudden cardiac death. Whether AAS-associated cardiomyopathy is reversible once AAS are withdrawn remains unsettled: published outcomes range from near-complete recovery to irreversible severe biventricular dysfunction. Here we report the case of a man first assessed at the age of 26, after 33 cumulative months of supraphysiological AAS abuse, and reassessed eight years later. Marked regression of concentric left ventricular hypertrophy, with an accompanying reduction in right ventricular free wall thickness, was documented: left ventricular (LV) mass index fell from 261 to 111 g/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.